Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 4/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.34 |
| ▸ | HTR2B | P41595 | 4/20 | 0.34 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320009 | 0.86 | CDK1 (0.41) | CDK1 | |
| SCHEMBL3315815 | 0.85 | CDK1 (0.39) | CDK1 | |
| SCHEMBL3318331 | 0.84 | YTHDC1 (0.53) | YTHDC1NT5EHTR2CHTR2BTMIGD3 | |
| SCHEMBL8128251 | 0.84 | CDK1 (0.37) | CDK1YTHDC1PIK3CDNT5EHTR2C | |
| SCHEMBL3322465 | 0.83 | YTHDC1 (0.54) | YTHDC1NT5EHTR2CHTR2BTMIGD3 | |
| SCHEMBL3174582 | 0.78 | STK17B (0.44) | KMT2AL3MBTL1 | |
| SCHEMBL3168722 | 0.77 | STK17B (0.45) | KMT2AL3MBTL1 | |
| SCHEMBL8135722 | 0.77 | CTSS (0.41) | PIK3CD | |
| SCHEMBL3169517 | 0.76 | STK17B (0.38) | KMT2AL3MBTL1 | |
| SCHEMBL8140037 | 0.76 | CDK1 (0.36) | CDK1CCNE1CDK2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-2028182-A1 | Cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-2028182-A1 | Cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-1972630-A1 | Purines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-24 | — | — | EP | disclosed |
| EP-1972630-A1 | Purines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008107368-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | CPN1, SERPINB1, PNP | CDK1 787/4885YTHDC1 3386/4885PIK3CD 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.